Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer’s drug.
A new class of Alzheimer’s treatments has proven a commercial disappointment over the past two years, but the Japanese pharmaceutical firm Eisai reported new data late Wednesday that analysts say could boost uptake of the drug it sells with Biogen.
Patients currently on Leqembi must travel twice monthly to infusion centers for an hourlong infusion, which can be a challenge for Alzheimer’s patients suffering from cognitive impairment or dementia. A subcutaneously injected version of Leqembi could theoretically be administered at home. “In our opinion these results suggest that Leqembi is viable,” TD Cowen analyst Phil Nadeau wrote late Wednesday. He said that the biggest risk was that regulators might ask Eisai for an additional trial testing a lower dose of the new injection to try to achieve lower ARIA rates. He rates Biogen stock at Outperform with a $305 target price.
Wall Street has remained skeptical, and peak sales expectations are nowhere near the $20 billion per year that analysts in 2021 projected Aduhelm would eventually hit.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biogen and Eisai release new Alzheimer’s drug data that may support wider uptakeEisai plans to apply for FDA approval of subcutaneous Leqembi by early next year
Read more »
Shots of Alzheimer's Drug Leqembi as Effective as IVAn injected version of Eisai and Biogen's Alzheimer's drug Leqembi works as well as the current intravenous version at removing toxic brain plaques, according to an analysis presented by Eisai on Wednesday. A weekly shot form of Leqembi, given as two consecutive injections,...
Read more »
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in studyEisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
Read more »
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in studyEisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
Read more »
When Saying “No” Isn’t EnoughThere are many parallels between drug use prevention programs and weight management programs.
Read more »
K-pop Star G-Dragon Arrested on Drug ChargesG-Dragon, one of South Korea's most famous idols, has reportedly been booked on drug charges.
Read more »